Sickle Cell Disease Treatment Market to Cross USD 17.7 Billion by 2034 at 18.5% CAGR, Driven by Gene Therapy Adoption and Rising Disease Prevalence

The global sickle cell disease treatment market was valued at US$ 2.7 Bn in 2023 and is projected to grow at a CAGR of 18.5% from 2024 to 2034, crossing US$ 17.7 Bn by the end of 2034. Market growth is being supported by advances in medical research, increasing awareness, growing healthcare investments, improved diagnostic capabilities, and the development of novel therapies targeting the underlying causes of sickle cell disease.

Gene therapies, gene-editing technologies, and innovative medications are transforming the treatment landscape. While conventional approaches such as pain management, blood transfusions, and hydroxyurea remain important, the development of gene-based interventions and other advanced therapies is creating new opportunities for long-term disease management.

The disease burden is particularly significant in sub-Saharan Africa and parts of Asia, while North America is expected to remain the leading regional market. By drug class, antimetabolites are projected to dominate the market, while Hemoglobin SS (HbSS) is expected to remain the leading disease type.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=65504

Analysts’ Viewpoint Regarding Sickle Cell Disease Treatment Market

The market for sickle cell disease treatment is experiencing substantial growth as breakthroughs in medical research and growing public understanding support the development and adoption of new therapies. Genetic-based approaches, gene-editing technologies, and novel medications are increasingly focused on addressing the underlying causes of the disease rather than solely managing symptoms.

Increasing healthcare funding, improved diagnostic tools, and the significant prevalence of sickle cell disease are further supporting market expansion. The burden is particularly high in sub-Saharan Africa and parts of Asia, creating an important need for accessible and effective treatment options.

Gene modification and gene-editing approaches could potentially provide long-term treatment options for individuals with sickle cell disease. The development of therapies such as crizanlizumab and gene therapies such as exagamglogene autotemcel is contributing to greater optimism around the treatment landscape.

However, improving access to advanced treatments remains an important challenge, particularly in developing countries where disease prevalence is high. Greater availability of affordable oral drugs, genetic treatments, and other advanced therapies will remain important for expanding patient access.

Sickle Cell Disease Treatment Market Overview

Sickle cell disease is a genetic blood disorder associated with the production of abnormal hemoglobin, causing red blood cells to adopt a crescent or sickle shape. These cells have reduced oxygen-carrying capability and can contribute to severe pain, fatigue, and organ damage.

The supplied source estimates that approximately 20–25 million people worldwide are affected by sickle cell disease. The highest burden is reported in sub-Saharan Africa, where approximately one in every 100–150 children is born with the disease. In the United States, approximately 100,000 individuals live with SCD, with the majority being of African American descent.

The treatment landscape traditionally includes pain management, blood transfusions, and hydroxyurea. However, research and development activities are increasingly focused on transformative approaches such as gene therapy, bone marrow transplantation, and CRISPR-based interventions.

Companies including Vertex Pharmaceuticals, bluebird bio, and Novartis are active in the evolving treatment landscape. Therapies such as crizanlizumab and exagamglogene autotemcel represent developments aimed at reducing painful crises, improving quality of life, and potentially addressing the underlying genetic basis of the disease.

Increasing Gene Therapy Adoption Propelling Sickle Cell Disease Treatment Market

Increasing adoption of gene therapy is one of the major factors supporting the growth of the sickle cell disease treatment market. Advances in genetic research, particularly technologies such as CRISPR-Cas9 gene editing, are creating new possibilities for treating inherited disorders.

Gene therapy focuses on the genetic cause of sickle cell disease rather than simply managing its symptoms. This creates the potential for long-term treatment outcomes and represents a significant shift in the therapeutic approach to genetic diseases.

CRISPR Therapeutics and Vertex Pharmaceuticals conducted a Phase III clinical trial involving CTX001, a gene-edited therapy for sickle cell disease. The therapy uses CRISPR-Cas9 technology to address the genetic mutation associated with the disease.

The clinical development of CTX001 and other similar therapies has contributed to growing interest among healthcare providers, patients, and pharmaceutical companies. Positive clinical results are supporting greater investment in genetic treatment research and encouraging the development of additional gene-based approaches.

As the treatment landscape transitions from therapies primarily focused on symptom relief toward approaches intended to address the underlying genetic mechanisms of congenital disorders, gene therapy is expected to remain a major area of market development.

Increasing Disease Prevalence and Severity Accelerating Market Growth

The increasing prevalence and severity of sickle cell disease are contributing to demand for more effective treatment options. The condition affects millions of people globally and can cause repeated episodes of severe pain known as vaso-occlusive crises.

According to the source, CDC estimates placed the number of people living with SCD in the United States at approximately 100,000 in May 2022. This substantial patient population creates continuing demand for disease management and treatment.

The severity of the disease is further reflected in the frequency of vaso-occlusive crises. A study cited from NCBI estimates that patients with SCD can experience up to 18 VOCs annually on average. Recurrent painful episodes create a significant burden for both patients and healthcare systems.

The development of therapies designed to reduce the frequency and severity of such episodes is therefore an important market growth factor. In November 2019, the FDA granted Pfizer's Oxbryta fast-track approval for adults and children aged 12 years and older. In 2021, the FDA expanded the approval to include children aged four years and older.

Oxbryta was developed to reduce the frequency of vaso-occlusive crises, illustrating the market's focus on therapies capable of addressing important clinical challenges associated with SCD.

Antimetabolites Dominate Drug Class Segment

The antimetabolites segment is projected to dominate the global sickle cell disease treatment market by drug class. Its position is supported by the established use of antimetabolite therapies, improvements in drug development, increasing disease awareness, and improvements in diagnosis.

Rising prevalence in regions such as sub-Saharan Africa and parts of the Middle East, combined with increasing healthcare investment, is supporting demand for effective treatment options. Antimetabolites remain important within the therapeutic landscape because of their established role in managing the disease.

Hydroxyurea is one of the most important antimetabolites used in sickle cell disease management and is described in the supplied source as a cornerstone of SCD treatment. The drug works by increasing fetal hemoglobin levels in red blood cells, which can reduce sickling and the frequency of painful crises.

Hydroxyurea has also been associated with reductions in hospitalization and blood transfusion requirements and improvements in quality of life among SCD patients. Its established therapeutic role supports the continued prominence of the antimetabolite segment.

Hemoglobin SS Leads Sickle Cell Disease Treatment Market by Disease Type

The Hemoglobin SS (HbSS) segment is projected to dominate the global sickle cell disease treatment market by disease type during the forecast period.

HbSS produces abnormal hemoglobin that contributes to sickling of red blood cells, obstruction of blood flow, recurrent painful crises, organ damage, and reduced life expectancy. The severity associated with this form of SCD creates substantial demand for ongoing medical intervention and treatment.

According to the supplied source, HbSS represents approximately 60%–80% of all SCD cases. Around 300,000 newborn babies worldwide are diagnosed with sickle cell disease each year, with a considerable number affected by HbSS, particularly in high-prevalence regions such as sub-Saharan Africa.

The United States also has a substantial HbSS patient population. Approximately 100,000 people are reported to live with SCD in the country, with approximately 60%–70% diagnosed with the HbSS type, according to the supplied source.

The combination of disease severity, prevalence, and need for ongoing treatment supports the leading position of HbSS within the global SCD treatment market.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=65504

North America Dominates Sickle Cell Disease Treatment Market

North America is expected to dominate the global sickle cell disease treatment market during the forecast period. Market growth in the region is supported by increasing awareness of SCD as a public health priority, particularly in the United States.

Approximately 100,000 people in the U.S. live with sickle cell disease, creating a substantial population requiring continuous treatment and care. According to the Centers for Disease Control and Prevention, the incidence of SCD is approximately one in 365 African American births and one in 16,300 Hispanic American births.

Hydroxyurea remains an important oral therapeutic agent in the U.S. market. Its established use has contributed to the continued importance of oral treatment approaches.

The regional treatment landscape has also benefited from the development and regulatory progress of therapies such as voxelotor, also known as Oxbryta, and crizanlizumab, known as Adakveo. Gene therapies have further expanded the treatment landscape and strengthened the region's role in advanced SCD treatment development.

Analysis of Key Players in Sickle Cell Disease Treatment Market

The competitive landscape includes Bristol-Myers Squibb Company, CRISPR Therapeutics, Novartis AG, Emmaus Medical, Inc., Bluebird bio Inc., Hoffmann-La Roche Ltd., Pfizer Inc., Vertex Pharmaceuticals Incorporated, Agios Pharmaceuticals, Inc., GlycoMimetics, Graphite Bio, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca, Hikma Pharmaceuticals PLC, and Addmedica, among others.

These companies are involved in developing, commercializing, or advancing therapies for sickle cell disease. The competitive landscape includes conventional drug-based approaches as well as innovative gene and genetic medicine technologies.

Companies are profiled based on parameters including company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. Competition analysis also includes a competition matrix and company-level market assessment.

Sickle Cell Disease Treatment Market Segmentation

The global sickle cell disease treatment market is segmented by drug class, disease type, age group, route of administration, distribution channel, and region.

By drug class, the market includes antimetabolites, amino acids, NSAIDs, monoclonal antibodies, and others, including analgesics and antipyretics. By disease type, the market is categorized into Hemoglobin SS (HbSS), Hemoglobin SC (HbSC), and Hemoglobin (HbS) beta thalassemia.

Based on age group, the market is divided into children and adults. By route of administration, it includes oral and parenteral treatments. Distribution channels comprise hospital pharmacies, retail pharmacies, and online pharmacies.

Regionally, the market covers North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Countries covered include the U.S., Canada, Germany, U.K., France, Italy, Benelux, Nordic Countries, China, India, Japan, South Korea, Brazil, Mexico, GCC Countries, South Africa, and Turkey.

Sickle Cell Disease Treatment Market Outlook

The global sickle cell disease treatment market is projected to expand from US$ 2.7 Bn in 2023 to more than US$ 17.7 Bn by 2034, advancing at a CAGR of 18.5% from 2024 to 2034.

Increasing gene therapy adoption, rising disease prevalence, and the high severity associated with SCD are expected to remain major growth drivers. Conventional treatments such as hydroxyurea continue to play an important role, while gene-editing technologies and advanced therapies are transforming the development pipeline.

The antimetabolites segment is expected to remain dominant by drug class, while HbSS is projected to lead by disease type. North America is expected to maintain its leading regional position, supported by patient population, treatment infrastructure, awareness, regulatory activity, and research capabilities.

At the same time, improving access to advanced therapies remains an important opportunity, particularly in regions with high disease burden. Continued development of genetic treatments, affordable oral medicines, and other advanced therapies is expected to shape the future trajectory of the global sickle cell disease treatment market.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=65504<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Cluster Headache Market

Neurotrophic Keratitis Market

Pharmaceutical Excipients Market

Menopausal Hot Flashes Treatment Market

Hyperphosphatemia Treatment Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com